Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes
Nicolas Margot, Renee R. Ram, Martin S. Rhee, Christian Callebaut
Abstract
= 40) indicated wild-type susceptibility to LEN (fold change ranging from 0.3 to 1.1), while reduced susceptibility was observed for control drugs. HIV GCSMs did not impact the activity of LEN, while some conferred resistance to MIs and PIs. Similarly, LEN activity was not affected by naturally occurring variations in HIV Gag, in contrast to the reduced susceptibility observed for MIs. Finally, the activity of LEN was not affected by the presence of resistance mutations to the 4 main antiretroviral (ARV) drug classes. These data support the evaluation of LEN in PWH with multiclass resistance.
Topics & Concepts
CapsidHuman immunodeficiency virus (HIV)Drug resistanceDosingVirologyMutantPhenotypeCleavage (geology)MedicineBiologyVirusPharmacologyChemistryMicrobiologyGeneticsGeneFracture (geology)PaleontologyHIV Research and TreatmentHIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions